Literature DB >> 3691576

Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data.

F Jehl1, M Adloff, H Monteil, J M Brogard.   

Abstract

The biliary disposition of ciprofloxacin was studied in 12 recently cholecystectomised patients during 24 hours following a single oral administration of 500 mg of the drug. Ciprofloxacin was measured in serum, urine, bile and faeces by both high performance liquid chromatography (HPLC) and bioassay. The results were found to be comparable for the concentrations in serum (mean Cmax = 0.97 +/- 0.17 microgram/ml by HPLC and 1.08 +/- 0.19 microgram/ml by bioassay) and in urine (0.6 h: 267 +/- 74 micrograms/ml and 241 +/- 58 micrograms/ml respectively). Higher concentrations were found in bile when measured by bioassay compared with HPLC (peak concentration = 10.3 +/- 3.4 micrograms/ml and 7.5 +/- 2.8 micrograms/ml respectively; p less than 0.02). The total biliary elimination was also significantly higher according to bioassay data (2167 +/- 288 micrograms/ml versus 1587 +/- 222 micrograms/ml; p less than 0.01). This suggests a first pass effect and hepatic biotransformation of ciprofloxacin to one or more active metabolite (s).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691576     DOI: 10.1007/BF03189885

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  24 in total

1.  Reduced enteral absorption of ciprofloxacin in the presence of antacids.

Authors:  G Höffken; K Borner; P D Glatzel; P Koeppe; H Lode
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

2.  High-performance liquid chromatographic method for determination of ciprofloxacin in biological fluids.

Authors:  F Jehl; C Gallion; J Debs; J M Brogard; H Monteil; R Minck
Journal:  J Chromatogr       Date:  1985-05-03

3.  Multiple-dose ciprofloxacin kinetics in normal subjects.

Authors:  G E Aronoff; C H Kenner; R S Sloan; S T Pottratz
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

4.  Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans.

Authors:  J M Brogard; F Comte; J Lavillaureix
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Jul-Sep       Impact factor: 2.441

5.  Diffusion of ciprofloxacin into prostatic fluid.

Authors:  A Dalhoff; W Weidner
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

6.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

7.  Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin.

Authors:  B Ledergerber; J D Bettex; B Joos; M Flepp; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

8.  Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine.

Authors:  B Joos; B Ledergerber; M Flepp; J D Bettex; R Lüthy; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

9.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

10.  Ciprofloxacin concentrations in tonsils following a single intravenous infusion.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1984 Sep-Oct       Impact factor: 3.553

View more
  2 in total

1.  Concentration of ciprofloxacin in non-functional gallbladder mucosa after single dose intravenous administration.

Authors:  I Sayek; V Kaynaroglu; H Scholl
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

Review 2.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.